Hope Medicine Trials and Fundraising

Hope Medicine LogoHair loss cure related funding is starting to boom. Most encouraging of all, China is finally joining the fray with new companies such as Hope Medicine and Kintor Pharmaceutical.

Please read this entire post for a history of Hope Medicine and Bayer’s HMI-115, which targets the prolactin receptor to cure hair loss.

Update: November 28, 2021

New CEO Henri Doods Interview

A reader sent me the below screenshot of Hope Medicine CEO Henri Doods’ Chinese magazine (page 17) interview that I mentioned earlier. If anyone can translate into English, please post in the comments. Click on the image to expand.

Hope Medicine Doods Interview
Hope Medicine CEO interview.

Update: September 20, 2021

Hope Medicine CEO Henri Doods
Hope Medicine CEO Henri Doods.

Reader “Karl” just notified us that there is a brand new cover page interview of Hope Medicine’s CEO Dr. Henri Doods in a Chinese magazine “tradetree.cn”. If anyone can gain access to it (see here) and translate into English, please try. Not worth purchasing as yet in my opinion.

Per Karl, Phase 2 clinical trials for hair loss product HMI-115 are planned for Q4 2021 (but no proof anywhere else). This matches what we expected per the prior updates that I discussed in May (see further below). Note that HMI-115 is the same as Bayer’s prolactin receptor antibody. Hope Medicine has the rights to the development of this product.

May 9, 2021

Hope Medicine (China) Raises $56 Million

Until now, Kintor Pharmaceutical (China) was the main reason for the excitement. However, this weekend, the participants on this site’s hair loss chat are discussing Hope Medicine. Out of the blue, this startup company received $56 million in a Series B round of financing. Investment firms Qiming Venture Partners and Grand Flight Investment led the way.

Other investors include: HighLight Capital; Sinovation Ventures (a venture capital firm led by former Google China head Kai-Fu Lee); and Trustbridge. More here.

Phase 2 Trials for HMI-115 (Bayer License) in 2021:

“Previously, HopeMed signed an exclusive license agreement with Bayer AG on the development and commercialization of a human antibody (HMI-115) targeting the prolactin (PRL) receptor for the treatment of male and female pattern hair loss. At present, HMI-115 has completed phase I clinical trials in the European Union, with positive safety results. The global multi-center phase II clinical trials for androgenic alopecia and will soon be launched.

Ruiping Xiao
Dr. Rui-Ping Xiao

Note that I first covered Hope Medicine in my 2019 post on its partnership with Bayer in regards to the prolactin receptor. The company was founded by Dr. Rui-Ping Xiao, the dean of the College of Future Technology of Peking University. Apparently, she is also an associate editor of the New England Journal of Medicine. Update: See this page for much more on Dr. Xiao Ruiping.

The most unusual part of this story is that Hope Medicine’s official website (hopemedinc.com) has not worked for weeks. I have e-mailed several of their employees, and will update this post if I get any response.

Increasing Hair Loss Company Funding

  • This latest news comes just one month after we heard that Aneira Pharma received $25 million from Valkyrie Group.
  • South Korea’s Han Bio also seems to have received enough funding to open its new dermal papilla storage plant in May 2021.
  • In September 2020, Stemson Therapeutics received $7.5 in additional funding.

35 thoughts on “Hope Medicine Trials and Fundraising”

  1. The number of different approaches is amazing: cell-culturing, dht/hormones, antibodies, cell-signaling pathways, wounding, gene/Crispr, prostaglandines, lactate,…

    I hope something comes to fruition.

    Btw Stemore of Korea also works on antibodies. They renamed their company: “Epibiotech” – I always wonder why that is necessary as they don’t market a product (yet).

    1. There are a lot of moves happening in South Korea that we don’t know about yet, I speculate

  2. I notice that topical finasteride named “Caretopic” is out in Italy, not galenic version, it’s an industrial versione.

  3. Great article and progress in hair loss treatment angles. Nice too see so many different approaches to fight mpb. Sad thing is we have a 99.9% chance these all fail and we are just stuck with big 3 again. Makes you think what is going on behind the scenes.

  4. I’m really excited to see some of the long term results of this treatment. I always guessed DHT was a reason for hair miniaturization but was not the sole culprit. Fingers crossed on this one. It will certainly be expensive. Is it an injection that will be required periodically life long? Or for a certain period of time?

  5. Tired of painting my scalp with dermach every morning.. can we please cure this? I need a life :(

    1. Pfff replicel didnt say anything new ! Whats going on with stemson therapeutic human trials that are set to begin this year ? Please thank you!

  6. Researchers have found a way to heal skin tissue without scar formation… at least in mice :D

    The crazy part is that those mice also generated new hair follicles in this process, might be interesting if this works for human heads as well after hair transplants! And the best thing is the drug has already been approved almost 20yrs ago by the FDA for a certain eye disease.

    1. That s sound crazy good no ? I mean if this could work, it would be the end of hairloss or almost for women in my case no ?
      With 50 mg of spironolactone i don’t have hairloss…if this could regenerate hair follicles
      then i would maintain my new hair follicle while on spiro…
      But does that mean we would have to really damage our scalp to do so ?

  7. Stemson is our cure.. Unlimited supply of hair, for all forms of hair loss.. Forget all other bs, like Tsuji, or Histogen.

    Stemson is it.

      1. That’s IF they make it and bring the cure to market. And believe me some people out there are ready to sell their kidneys for the cure.

  8. You are already going down a path again where people will undoubtedly be disappointed in the end. If you read their statement in depth it clearly states, that they have fda clearance to enter a clinical trial for the condition “endometriosis”. This will not be a trial for male pattern baldness. In fact the term “hair” is only mentioned three times in that text and two times its part of the word “chairman” lol. I think they are going ahead with endometriosis for now because it would be a condition covered by insurance companies and the anti body will be very costly. I am afraid, that trials and development for AA will take much longer than that if they will happen at all. Thats the reality, hair loss is a non priority for companies like this.

  9. Has anyone here used topical dutasteride from Strut? At $69 for a 30 day supply, I’m considering it, if it works well. I’d appreciate any feedback if there are any Strut users here.

    1. @Rick – Have you looked into Happy Head’s topical formulation? They use fin instead of dut, but also higher concentration of minox. I might try that next year, but in the meantime, I’m experimenting with something else and want to give it 4-6 months. I think we’re all just biding time until something like Kintor comes out. Let’s face it – the Big 3 are less than ideal.

  10. So how will the potent monoclonal prolactin (PRL) receptor antibody be administered? Like regerons antibody cocktail through an IV?

  11. Hey, has anyone ever tried microneedling by itself (w/o minox, fina, etc.)? Only my temples are shedding from now, I’d like to try but not sure about the efficacy. Thx.

  12. Dr. Chen answered everyone’s questions in the FAK inhibitor post FYI. Doubt he will have time to come back again, and the research is still not in human trials. So no use getting too excited this early in the game!

    1. Unfortunately, the image size was too large and this was the best I could do after optimizing. Make sure you clicked on the image to open in a separate tab (where it looks a bit clearer and larger).

Leave a Reply

Your email address will not be published. Required fields are marked *